12th Jun 2018 15:55
PRESS RELEASE
FOR IMMEDIATE RELEASE
Results of 2018 Annual General Meeting
London, UK - 12 June 2018: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that all resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.
Resolutions 1 to 5 were passed on a show of hands.
Details of proxy results were as follows:
Resolution number | Votes for | Votes against | Abstentions |
1 | 21,318,347 | Nil | Nil |
2 | 21,317,894 | Nil | 453 |
3 | 21,317,894 | Nil | 453 |
4 | 19,056,035 | Nil | 2,262,312 |
5 | 21,317,894 | Nil | 453 |
Details of voting results for resolutions 6 and 7 (including proxies) were as follows:
Resolution number | Votes for | Votes against | Abstentions |
6 | 30,158,064 | 2,351,500 | 520 |
7 | 25,689,064 | 6,820,500 | 520 |
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503205 | |
Stephen Stamp (Chief Executive Officer) | ||
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | |
Michael Meade / Freddie Barnfield (Nominated Adviser) | ||
James Black (Joint Broker) | ||
N+1 Singer | Tel: +44 (0) 20 7496 3000 | |
Aubrey Powell (Joint Broker) | ||
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 | |
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner | ||
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 | |
Anne Hennecke | ||
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
Related Shares:
ERGO.L